Real-world dose escalation of biologics for moderate-to-severe psoriasis in the United States

Real-world dose escalation of biologics for moderate-to-severe psoriasis in the United States

Aim To compare real-world dose escalation of risankizumab with other US Food and Drug Administration (FDA)-approved biologic treatments for management of moderate-to-severe psoriasis (PsO) in the United States. Methods The Merative® MarketScan® Research Database was used to identify adults with ≥2 m...

Full description

Bibliographic Details
Main Authors: Jashin J. Wu, Manish Patel, Feng Zeng, Ahong Huang, Xing Pan, Yiwen Cao, Naijun Chen, Huzefa Photowala, Vishvas Garg, Jeff Crowley
Format: Article
Language:English
Published: Taylor & Francis Group 2023-12-01
Series:Journal of Dermatological Treatment
Subjects:
psoriasis
real-world data
dose escalation
Online Access:http://dx.doi.org/10.1080/09546634.2023.2200869

Internet

http://dx.doi.org/10.1080/09546634.2023.2200869

Similar Items